Mirum Pharmaceuticals, Inc. Foreign Currency Transaction Gain (Loss), Unrealized
Mirum Pharmaceuticals, Inc. (MIRM) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$900.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$900.00K, a 250.00% decline year-over-year.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$1.10M, a 266.87% decline year-over-year.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$193.00K, a 229.53% decline year-over-year.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $643.00K.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $1.72M, a 39.72% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $1.23M.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$1.76M.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2022 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$900.00K 10-Q · filed 2026-08-05 | -$1.99M 10-Q · filed 2026-08-05 | -$2.19M derived: sum of 3 quarters · filed 2026-08-05 | -$1.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.10M 10-Q · filed 2026-05-06 | -$1.29M derived: sum of 2 quarters · filed 2026-05-06 | -$648.00K derived: sum of 3 quarters · filed 2026-05-06 | -$48.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $450.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.05M derived: sum of 3 quarters · filed 2026-08-05 | $1.72M 10-K · filed 2026-02-25 |
| 2025-09-30 | $643.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.24M derived: sum of 2 quarters · filed 2026-08-05 | $1.91M 10-Q · filed 2025-11-04 | $2.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $600.00K 10-Q · filed 2026-08-05 | $1.27M 10-Q · filed 2026-08-05 | $1.41M derived: sum of 3 quarters · filed 2026-08-05 | $407.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $658.00K 10-Q · filed 2026-05-06 | $807.00K derived: sum of 2 quarters · filed 2026-05-06 | -$193.00K derived: sum of 3 quarters · filed 2026-05-06 | $207.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$851.00K derived: sum of 2 quarters · filed 2026-02-25 | -$451.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.23M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$1.00M 10-Q · filed 2024-11-12 | -$600.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.08M 10-Q · filed 2025-11-04 | -$1.86M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $400.00K 10-Q · filed 2024-08-07 | $2.09M 10-Q · filed 2025-08-06 | -$860.00K derived: sum of 3 quarters · filed 2026-02-25 | $540.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.73M 10-Q · filed 2025-05-07 | -$1.26M derived: sum of 2 quarters · filed 2026-02-25 | $140.00K derived: sum of 3 quarters · filed 2026-02-25 | $140.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.59M derived: sum of 2 quarters · filed 2026-02-25 | -$1.59M derived: sum of 3 quarters · filed 2026-02-25 | -$1.76M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-12 | $1.40M derived: sum of 2 quarters · filed 2024-11-12 | $1.23M 10-Q · filed 2024-11-12 | $1.40M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |